News
PRISMAFLEX INTERNATIONAL : Evolution in the capital standing for Anthem Displays
Prismaflex partner up with Circle Graphics and maintain a minority holding via their Prismaflex USA subsidiary of 28.91%.
Prismaflex International announce they have concluded an association
EOS imaging Announces Its Financial Agenda For 2021
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP ANNOUNCE THE CREATION AND FUNDING OF NEW JOINT PUBLIC/PRIVATE LABORATORY "NEUROIMAGING FOR DRUG DISCOVERY" (NI2D)
The laboratory obtained funding of €350,000 from the French National Research Agency (ANR).
Lyon, 18 December 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of
GECI INTERNATIONAL : 2020-21 FIRST-HALF EARNINGS
At the Board meeting on December 17, 2020, the Directors reviewed and approved the 2020-21 half-year financial statements for the period ended September 30, 2020.
€m 2020-21 (6 months)
Madvertise - Acquisition of a strategic stake in SYNC
Press Release
Paris, 17 December 2020 – 6 pm
Acquisition of a strategic stake in SYNC
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French AdTech company dedicated to mobile advertising
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Regulatory News:
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna
Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
PRISMAFLEX INTERNATIONAL : 2020-2021 half-year results: Limited decline in results in light of the Covid-19 health crisis
2020-2021 six-month period analysis
- S1 activity down by 27% against a background of an economic environment deteriorated by the health crisis
- EBITDA positive at €0.3 million following careful
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the "Company" or "GenSight"), a biopharma company focused on developing and
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
DOLFINES (EX DIETSWELL) : Success of DOLFINES' 1.2 million euros Private Placement
PRESS RELEASE Paris, December 9, 2020
With the new success of a €1.2 million Private Placement with European investors, DOLFINES continues to strengthen its industrial and commercial capacity
GROUPE LDLC : 2020-2021 FIRST HALF RESULTS UP SHARPLY
- FIRST HALF CONSOLIDATED REVENUES OF €314.3M, UP 41.6% (UP 21.0% AT CONSTANT CONSOLIDATION SCOPE)
- GROSS MARGIN UP 2.9 PP TO 21.9%
- OVER FIVE-FOLD INCREASE IN EBITDA TO €25.6M, I.E. 8.1% OF
iBiopsy®: Promising Results on a Preliminary Study to Identify the Severity of the Disease in Patients With Non-Alcoholic Steatohepatitis (NASH)
Regulatory News:
Median Technologies (ALMDT)(Paris:ALMDT), The Imaging Phenomics Company®, announces today the results of a preliminary retrospective study on the evaluation of the severity of
DOLFINES (EX DIETSWELL) : Success of DOLFINE' Private Placement carried out with a European investor
PRESS RELEASE Paris, November 24, 2020
Success of DOLFINES' private placement
carried out with a European investor
DOLFINES, an independent specialist in engineering and services for the renewable
Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS : THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUES A FAVORABLE OPINION ON THE PRECLINICAL DEVELOPMENT PLAN SUBMITTED BY THERANEXUS AND BBDF
Lyon, 19 November 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) announced securement of the
DOLFINES (EX DIETSWELL) : Signing of a MOU with 8.2 France
PRESS RELEASE Paris, November 12, 2020
Signing of a Memorandum Of Understanding between DOLFINES and 8.2 France to offer a combination of their expertise for the renewable energy market
DOLFINES, an
AGROGENERATION : General Meeting to be held behind closes doors on November 26, 2020 - Transfer of the Company's registered office
Paris, November 6th, 2020
Amid the ongoing COVID-19 epidemic and in line with government measures to slow the spread of the virus, the Company's General Meeting will be held on November 26, 2020
Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE)
THERANEXUS : PRESENTATION OF THE RESULTS OF THE PHASE IB CLINICAL STUDY OF THN201 FOR ALZHEIMER'S DISEASE AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
The conference will take place remotely from 4 to 7 November 2020.
Lyon, 4 November 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer
MND : Hebei Tourism Investment chose MND for Jinshanling Golden Mountain ski resort in China
MND (Euronext Growth - FR0011584549 - ALMND), via its MND SNOW business line, world's second largest player in the snowmaking market, has won, alongside its Chinese partner Beijing Snow Elan, the
GenSight Biologics Reports Validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Sensorion Announces Attendance and a Presentation at Upcoming Conferences
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
DIETSWELL : DOLFINES INTERIM RESULTS 2020
PRESS RELEASE Paris, October 30, 2020
1st HALF 2020 RESULTS
DOLFINES (formerly DIETSWELL), an independent specialist in engineering and services for the renewable and conventional energy industry
Madvertise - HALF-YEARLY GROWTH RESULTS 2020
Press Release Paris, 28 October 2020 - 6:45 pm
HALF-YEARLY GROWTH RESULTS 2020
- Confirmed resistance of the activity
- Beautiful dynamics of Germany (+24%)
- Improvement in the Group's overall